<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313962</url>
  </required_header>
  <id_info>
    <org_study_id>AIT02-11-01</org_study_id>
    <nct_id>NCT01313962</nct_id>
  </id_info>
  <brief_title>Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of Flufirvitide-3 Nasal Spray in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autoimmune Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autoimmune Technologies, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetic profile of
      flufirvitide-3 nasal spray in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Flufirvitide-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flufirvitide-3 0.05 mg single dose</intervention_name>
    <description>Nasal Spray</description>
    <arm_group_label>Flufirvitide-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flufirvitide-3, 0.1 mg single dose</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>Flufirvitide-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flufirvitide-3, 0.2 mg single dose</intervention_name>
    <description>nasal spray</description>
    <arm_group_label>Flufirvitide-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flufirvitide-3, 0.4 mg single dose</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>Flufirvitide-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study-specific
             procedures.

          -  Subjects must be able to understand and be willing to comply with study procedures,
             restrictions, and requirements.

          -  Healthy male and non-fertile female subjects aged 18 and 55 years inclusive

          -  Female subjects must have a negative urine pregnancy test at screening must not be
             lactating or breastfeeding and must be of non-childbearing potential

          -  Male subjects should be willing to use barrier contraception during sexual
             intercourse,

          -  Body weight 50 to 100 kg inclusive and body mass index (BMI) 18 to 30 kg/m2 inclusive.

          -  Clinically non-significant findings on physical examination in relation to age.

          -  Negative Rapid Flu Test (TRU FLUÂ® kit)

          -  Negative nasal examination upon admission to the study center.

        Exclusion Criteria:

          -  History and/or presence of any clinically significant disease or disorder such as
             cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and
             psychiatric/mental disease/disorders,

          -  History and/or presence of hepatic or renal disease or any other condition known to
             interfere with the absorption, distribution, metabolism, or excretion of drugs.
             Subjects with a surgical history of the gastrointestinal tract should also be excluded
             from participation in the study.

          -  Any clinically significant illness, medical/surgical procedure, or trauma within 4
             weeks of the administration of the investigational product which is symptomatic enough
             to affect study conduct or the well-being of the subject

          -  History and/or presence of asthma or recurrent sinusitis. Active rhinitis at screening
             or upon admission to the study center.

          -  Any clinically significant nasal septum deviation, presence of septum perforations,
             and history of recurrent epistaxis and nasal polyps.

          -  Subjects with a history of sinus surgery and/or persistent hypertrophic inferior
             turbinates.

          -  History of vaccination with live vaccine within 7 days or attenuated vaccine within 14
             days of the administration of the investigational product.

          -  Any clinically significant abnormalities in clinical laboratory safety assessment
             results

          -  A positive result at screening on serum hepatitis B surface antigen, hepatitis C
             antibodies and HIV antibodies.

          -  Significant orthostatic reaction at screening or upon admission to the study center as
             judged by the Principal Investigator.

          -  Abnormal vital signs, after 5 minutes supine rest,

          -  Any clinically significant abnormalities in rhythm, conduction, or morphology of
             resting electrocardiogram (ECG) that may interfere with the interpretation of QTc
             interval changes.

          -  Prolonged QTcF greater than 450 ms or shortened QTcF less than 360 ms or family
             history of long QT syndrome.

          -  Known or suspected drugs of abuse or alcohol abuse or dependence

          -  Positive screen for drugs of abuse or alcohol at screening or upon admission to the
             study center.

          -  Excessive intake of caffeine-containing foods or beverages within 48 hours prior to
             the admission to the study center.

          -  Use of drugs with enzyme-inducing properties such as St John's Wort, within 3 weeks
             prior to the administration of the investigational product.

          -  Abstain from smoking from 30 days prior to screening and for the duration of the
             study.

          -  Use of any prescribed medication as well as any over-the-counter/non prescribed/
             herbal medicines, within 2 weeks prior to administration of the investigational
             product.

          -  Use of any nasal steroid 3 months prior to the administration of the investigational
             product.

          -  Involvement in the planning and/or conduct of the study

          -  Have received another new chemical entity or has participated in any other clinical
             study that included drug treatment within 3 months prior to administration of the
             investigational product in this study.

          -  Previous randomization of treatment in the present study or any other study with
             Flufirvitide-3.

          -  Plasma donation within 4 weeks prior to enrollment or blood donation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Hopkins, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Autoimmune Technologies, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Phase One Services</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiviral</keyword>
  <keyword>intranasal</keyword>
  <keyword>influenza</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

